Efficacy of prophylactic potassium-competitive acid blockers after catheter ablation for atrial fibrillatio

Not Applicable

• Conditions: Diseases of the circulatory system

• Registration Number: KCT0009272
• Lead Sponsor: The Catholic University of Korea, Seoul St. Mary's Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 2 April 2024

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

i) Underwent radiofrequency ablation or cryoballoon ablation for atrial fibrillation.
ii) Age 19 to 90 years inclusive.

Exclusion Criteria

i) Patients with moderate or severe liver impairment, or renal impairment (Serum Cr > 1.5 mg/dl).
ii) Patients with cognitive impairments that make it difficult to understand the study.
iii) Pregnant or breastfeeding patients, or those not willing to maintain contraception during the study period.
iv) Patients with hypersensitivity to fexuprazan, or those with galactose intolerance, lactase deficiency, or glucose-galactose malabsorption.
v) Patients taking contraindicated medications such as atazanavir, nelfinavir, or rilpivirine.
vi) Patients who have taken Proton Pump Inhibitors (PPI) or PCAB agents for gastroesophageal reflux disease within 2 weeks prior to study enrollment.
vii) Other patients for whom the clinical administration of PCAB is considered difficult.

Study & Design

• Study Type: Interventional Study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Esophagogastric symptom questionnaire score ;Esophagogastric symptom questionnaire score

Secondary Outcome Measures

Name	Time	Method
Occurrence rate of esophagoatrial fistula;New prescription of gastrointestinal medication;Other gastrointestinal complications